Journal article
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: Findings from the breast cancer family registry
AW Kurian, GD Gong, EM John, DA Johnston, A Felberg, DW West, A Miron, IL Andrulis, JL Hopper, JA Knight, H Ozcelik, GS Dite, C Apicella, MC Southey, AS Whittemore
Journal of Clinical Oncology | Published : 2011
Abstract
Purpose: Women with germline BRCA1 and BRCA2 mutations have five- to 20-fold increased risks of developing breast and ovarian cancer. A recent study claimed that women testing negative for their family-specific BRCA1 or BRCA2 mutation (noncarriers) have a five-fold increased risk of breast cancer. We estimated breast cancer risks for noncarriers by using a population-based sample of patients with breast cancer and their female first-degree relatives (FDRs). Patients and Methods: Patients were women with breast cancer and their FDRs enrolled in the population-based component of the Breast Cancer Family Registry; patients with breast cancer were tested for BRCA1 and BRCA2 mutations, as were FD..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
Supported by Grants No. RFA-CA-06-503 from the National Cancer Institute, National Institutes of Health (NIH), No. CA69417 and CA94069 from NIH, No. U01 CA69467 from Cancer Care Ontario, No. U01 CA694117 from the Cancer Prevention Institute of California, and No. U01 CA69638 from the University of Melbourne, and through cooperative agreements with members of the Breast Cancer Family Registry and principal investigators.